TECH BIO-TECHNE Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: TECH

Price (delayed)

$73.41

Market cap

$11.55B

P/E Ratio

43.96

Dividend/share

$0.32

EPS

$1.67

Enterprise value

$11.67B

Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's ...

Highlights
TECH's P/E is 32% below its 5-year quarterly average of 64.3 and 18% below its last 4 quarters average of 53.3
BIO-TECHNE's debt has decreased by 18% YoY and by 15% QoQ
The net income has increased by 24% YoY but it has decreased by 10% from the previous quarter
TECH's EPS is up by 24% year-on-year but it is down by 10% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.bio-techne.com/
Peers: TMO BDX BIO STEM

Key stats

What are the main financial stats of TECH
Market
Shares outstanding
157.28M
Market cap
$11.55B
Enterprise value
$11.67B
Valuations
Price to earnings (P/E)
43.96
Price to book (P/B)
6.31
Price to sales (P/S)
10.29
EV/EBIT
35.44
EV/EBITDA
26.9
EV/Sales
10.42
Earnings
Revenue
$1.12B
EBIT
$329.3M
EBITDA
$433.88M
Free cash flow
$251.98M
Per share
EPS
$1.67
Free cash flow per share
$1.6
Book value per share
$11.64
Revenue per share
$7.13
TBVPS
$5.9
Balance sheet
Total assets
$2.36B
Total liabilities
$536.3M
Debt
$289.16M
Equity
$1.83B
Working capital
$436.79M
Liquidity
Debt to equity
0.16
Current ratio
4.4
Quick ratio
2.97
Net debt/EBITDA
0.29
Margins
EBITDA margin
38.7%
Gross margin
68.3%
Net margin
23.4%
Operating margin
26.4%
Efficiency
Return on assets
11.3%
Return on equity
15%
Return on invested capital
35.6%
Return on capital employed
14.7%
Return on sales
29.4%
Dividend
Dividend yield
0.44%
DPS
$0.32
Payout ratio
19.2%

TECH stock price

How has the BIO-TECHNE stock price performed over time
Intraday
1.2%
1 week
1.17%
1 month
1%
1 year
-32.57%
YTD
-11.43%
QTD
-11.43%

Financial performance

How have BIO-TECHNE's revenue and profit performed over time
Revenue
$1.12B
Gross profit
$764.76M
Operating income
$295.23M
Net income
$261.82M
Gross margin
68.3%
Net margin
23.4%
The net income has increased by 24% YoY but it has decreased by 10% from the previous quarter
BIO-TECHNE's net margin has increased by 15% YoY but it has decreased by 10% QoQ
The company's operating income rose by 12% YoY
The gross profit rose by 9% YoY

Growth

What is BIO-TECHNE's growth rate over time

Valuation

What is BIO-TECHNE stock price valuation
P/E
43.96
P/B
6.31
P/S
10.29
EV/EBIT
35.44
EV/EBITDA
26.9
EV/Sales
10.42
TECH's P/E is 32% below its 5-year quarterly average of 64.3 and 18% below its last 4 quarters average of 53.3
TECH's EPS is up by 24% year-on-year but it is down by 10% since the previous quarter
The stock's price to book (P/B) is 19% less than its last 4 quarters average of 7.8 and 17% less than its 5-year quarterly average of 7.6
BIO-TECHNE's equity has increased by 7% YoY and by 4.3% from the previous quarter
The price to sales (P/S) is 20% lower than the 5-year quarterly average of 12.8 and 17% lower than the last 4 quarters average of 12.4
The revenue has grown by 9% YoY

Efficiency

How efficient is BIO-TECHNE business performance
BIO-TECHNE's ROIC has increased by 34% YoY but it has decreased by 9% from the previous quarter
TECH's return on sales is up by 32% year-on-year but it is down by 8% since the previous quarter
TECH's return on assets is up by 20% year-on-year but it is down by 10% since the previous quarter
BIO-TECHNE's return on equity has increased by 15% YoY but it has decreased by 12% QoQ

Dividends

What is TECH's dividend history
Dividend details
DPS
$0.32
Dividend yield
0.44%
Payout ratio
19.2%
Recent dividends

Financial health

How did BIO-TECHNE financials performed over time
TECH's current ratio is up by 15% YoY and by 10% from the previous quarter
BIO-TECHNE's total liabilities has decreased by 11% YoY and by 11% QoQ
BIO-TECHNE's debt is 84% lower than its equity
TECH's debt to equity is down by 24% year-on-year and by 20% since the previous quarter
BIO-TECHNE's debt has decreased by 18% YoY and by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.